Variable Bcl-2 phenotype in benign and malignant lesions of urothelium
- 1 June 1998
- journal article
- Published by Elsevier in Cancer Letters
- Vol. 128 (1) , 87-92
- https://doi.org/10.1016/s0304-3835(98)00055-x
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Expression of the cell death-inducing gene bax in carcinomas developed from the follicular cells of the thyroid glandJournal of Clinical Endocrinology & Metabolism, 1996
- Prognostic Value of Bcl-2 and p53 Expression in Urinary Tract Transitional Cell CancerJNCI Journal of the National Cancer Institute, 1996
- Mapping of the human BAX gene to chromosome 19q13.3–q13.4 and isolation of a novel alternatively spliced transcript, BAXδGenomics, 1995
- mRNA and protein expression of p53 mutations in human bladder cancer cell linesCancer Letters, 1994
- CORRELATION OF p53 PROTEIN EXPRESSION IN HUMAN UROTHELIAL TRANSITIONAL CELL CANCERS WITH MALIGNANT POTENTIAL AND PATIENT SURVIVALInternational Journal of Urology, 1994
- p21 is a universal inhibitor of cyclin kinasesNature, 1993
- Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programed cell deathCell, 1993
- p53 is required for radiation-induced apoptosis in mouse thymocytesNature, 1993
- p53 Mutations in Human CancersScience, 1991
- Expression of intercellular adhesion molecule‐1 (ICAM‐1) on renal‐cell cancer: Possible significance in host immune responsesInternational Journal of Cancer, 1990